# Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis

> **NCT00603785** · PHASE4 · WITHDRAWN · sponsor: **University of California, San Francisco**

## Conditions studied

- Chronic Sinusitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Xolair

## Key facts

- **NCT ID:** NCT00603785
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Insufficient funds available
- **Last updated:** 2020-02-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00603785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00603785, "Effects of Anti-IgE Antibody Omalizumab on Patients With Chronic Sinusitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00603785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*